Bio-Rad Laboratories Inc

Bio-Rad Laboratories, Inc. manufactures and supplies a range of systems and products to separate biological and chemical materials, and to identify, purify, and analyse their components. Operating internationally, these products and systems are supplied to the clinical diagnostic and life science research markets. Founded in 1952, Bio-Rad Laboratories has its headquarters in Hercules, California. Bio-Rad operates through two segments: Clinical Diagnostics and Life Science. The company's Clinical Diagnostics segment handles the design, manufacture, sale, and support of test systems, informatics systems, specialised quality controls, and test kits that are used in clinical laboratories. The Life Science segment handles the development, marketing, and manufacture of approximately 6,000 reagents, instruments, and software. Available on the NYSE, stock for Bio-Rad Laboratories is listed under the ticker BIO. Bio-Rad products are available through the company's direct sales force, in addition to through a network of resellers, brokers, agents, and distributors. In April 2020, Bio-Rad announced that it had acquired Celsee, Inc., a single-cell analysis solutions provider, in a deal for an undisclosed amount. Bio-Rad reported that it expected the acquisition to extend the company's reach into precision medicine and single-cell analysis. Keep up to date on the latest share price changes by adding BIO stock to your eToro watchlist.